Investment Rating - The investment rating for the company is "Accumulate" (maintained) [6] Core Views - The company reported a revenue of 879 million yuan for H1 2025, representing a year-on-year increase of 19%, and a net profit attributable to shareholders of 115 million yuan, also up 19% year-on-year [1] - Q2 2025 revenue was 353 million yuan, down 15% year-on-year, with a net profit of 54 million yuan, down 1% year-on-year [1] - The company is expected to recover growth in Q3 2025 due to stabilizing tariff policies and improved production capacity in Malaysia [2] - The company's gross margin for H1 2025 was 34.42%, a decrease of 1.66 percentage points year-on-year, but Q2 2025 gross margin improved to 38.33%, an increase of 4.99 percentage points year-on-year [3] - The company’s net profit margin for H1 2025 was 13.10%, with Q2 2025 net profit margin at 15.18%, an increase of 2.03 percentage points year-on-year [4] - The company’s nursing robot project was selected for a government pilot program, indicating strong market potential for this segment [5] - Revenue projections for 2025-2027 are 2.315 billion yuan, 2.991 billion yuan, and 3.712 billion yuan, with year-on-year growth rates of 31.26%, 29.18%, and 24.11% respectively [10]